"Fetomaternal haemorrhage is a condition in which fetal erythrocytes infiltrate maternal circulation. When the physiological barrier between the maternal and the fetal circulation is disrupted, the positive pressure gradient may cause fetal erythrocytes to pass into the maternal circulation. The most clinically significant event during which fetomaternal haemorrhage most often occurs is labor. The incompatibility of erythrocyte antigens between mother and fetus may, as a result of fetomaternal haemorrhage, lead to the development of alloimmunization of the mother and maternal antibodies may cause hemolytic disease of the fetus and newborn. For this reason, in situations where there is a risk of fetomaternal haemorrhage by RhD positive erythrocytes, prevention of RhD alloimmunization is performed by administering anti-D immunoglobulin to RhD negative women. Excessive fetomaternal haemorrhage may put the fetus and newborn at risk of anemia."@en . "5"^^ . "[A11FB34AB3A6]" . . "1212-4184" . . . . "RIV/61989592:15110/12:33140716!RIV13-MSM-15110___" . "15110" . "3" . . . . "Erythrocyte alloimmunization in pregnant women Hemolytic disease of the fetus and newborn"@en . "anti-D immunoglobulin; haemolytic disease; red cell alloimmunization; fetomaternal haemorrhage"@en . "14" . "RIV/61989592:15110/12:33140716" . "Erytrocyt\u00E1rn\u00ED aloimunizace t\u011Bhotn\u00FDch \u017Een Hemolytick\u00E1 nemoc plodu a novorozence" . "2"^^ . . . . "Erythrocyte alloimmunization in pregnant women Hemolytic disease of the fetus and newborn"@en . "\u013Dubu\u0161k\u00FD, Marek" . . "2"^^ . "Proch\u00E1zka, Martin" . . . "Erytrocyt\u00E1rn\u00ED aloimunizace t\u011Bhotn\u00FDch \u017Een Hemolytick\u00E1 nemoc plodu a novorozence"@cs . "134703" . "CZ - \u010Cesk\u00E1 republika" . "I" . . "Ka\u017Ed\u00FD \u010Dlov\u011Bk, kter\u00FD postr\u00E1d\u00E1 antigen \u010Derven\u00E9 krevn\u00ED bu\u0148ky a je mu vystaven, si vytv\u00E1\u0159\u00ED protil\u00E1tku. Jestli\u017Ee plod zd\u011Bd\u00ED od otce n\u011Bkter\u00FD antigen krevn\u00EDch skupin p\u0159\u00EDtomn\u00FD na povrchu fet\u00E1ln\u00EDch erytrocyt\u016F a sou\u010Dasn\u011B tento antigen nevlastn\u00ED i matka, m\u016F\u017Ee n\u00E1sledkem fetomatern\u00E1ln\u00ED hemoragie (viz Fetomatern\u00E1ln\u00ED hemoragie) v pr\u016Fb\u011Bhu t\u011Bhotenstv\u00ED nebo p\u0159i porodu doj\u00EDt ke stimulaci jej\u00EDho imunitn\u00EDho syst\u00E9mu a tvorb\u011B protil\u00E1tek - %22aloimunizaci%22. Stejnou imunitn\u00ED reakci m\u016F\u017Ee u matky vyvolat i transf\u00FAze antigenn\u011B inkompatibiln\u00EDch erytrocyt\u016F. Mate\u0159sk\u00E9 hemolytick\u00E9 aloprotil\u00E1tky mohou v pr\u016Fb\u011Bhu t\u011Bhotenstv\u00ED pronikat placentou do krevn\u00EDho ob\u011Bhu plodu a nav\u00E1\u017E\u00ED se na fet\u00E1ln\u00ED erytrocyty, kter\u00E9 jsou n\u00E1sledn\u011B destruov\u00E1ny v retikulo-endoteli\u00E1ln\u00EDm syst\u00E9mu plodu. Rozv\u00EDj\u00ED se hemolytick\u00E9 onemocn\u011Bn\u00ED plodu a novorozence (HDFN - Haemolytic Disease of the Fetus and Newborn). Nen\u00ED-li aloimunizace matky diagnostikov\u00E1na a hemolytick\u00E9 onemocn\u011Bn\u00ED plodu nebo novorozence l\u00E9\u010Deno, m\u016F\u017Ee v\u00E9st k z\u00E1va\u017En\u00E9 perinat\u00E1ln\u00ED morbidit\u011B i mortalit\u011B. Dojde-li v pr\u016Fb\u011Bhu t\u011Bhotenstv\u00ED k prvn\u00EDmu kontaktu imunitn\u00EDho syst\u00E9mu matky s inkompatibiln\u00EDm erytrocyt\u00E1rn\u00EDm antigenem plodu, vznik\u00E1 z\u00E1va\u017En\u00E1 forma hemolytick\u00E9ho onemocn\u011Bn\u00ED ve st\u00E1vaj\u00EDc\u00EDm t\u011Bhotenstv\u00ED jen vz\u00E1cn\u011B. Z\u00E1va\u017Enou formou hemolytick\u00E9 nemoci jsou v\u011Bt\u0161inou ohro\u017Eeny antigenn\u011B inkompatibiln\u00ED plody a\u017E v n\u00E1sleduj\u00EDc\u00EDch t\u011Bhotenstv\u00EDch."@cs . "Erytrocyt\u00E1rn\u00ED aloimunizace t\u011Bhotn\u00FDch \u017Een Hemolytick\u00E1 nemoc plodu a novorozence" . . . . "Erytrocyt\u00E1rn\u00ED aloimunizace t\u011Bhotn\u00FDch \u017Een Hemolytick\u00E1 nemoc plodu a novorozence"@cs . "Postgradu\u00E1ln\u00ED medic\u00EDna" . "Ka\u017Ed\u00FD \u010Dlov\u011Bk, kter\u00FD postr\u00E1d\u00E1 antigen \u010Derven\u00E9 krevn\u00ED bu\u0148ky a je mu vystaven, si vytv\u00E1\u0159\u00ED protil\u00E1tku. Jestli\u017Ee plod zd\u011Bd\u00ED od otce n\u011Bkter\u00FD antigen krevn\u00EDch skupin p\u0159\u00EDtomn\u00FD na povrchu fet\u00E1ln\u00EDch erytrocyt\u016F a sou\u010Dasn\u011B tento antigen nevlastn\u00ED i matka, m\u016F\u017Ee n\u00E1sledkem fetomatern\u00E1ln\u00ED hemoragie (viz Fetomatern\u00E1ln\u00ED hemoragie) v pr\u016Fb\u011Bhu t\u011Bhotenstv\u00ED nebo p\u0159i porodu doj\u00EDt ke stimulaci jej\u00EDho imunitn\u00EDho syst\u00E9mu a tvorb\u011B protil\u00E1tek - %22aloimunizaci%22. Stejnou imunitn\u00ED reakci m\u016F\u017Ee u matky vyvolat i transf\u00FAze antigenn\u011B inkompatibiln\u00EDch erytrocyt\u016F. Mate\u0159sk\u00E9 hemolytick\u00E9 aloprotil\u00E1tky mohou v pr\u016Fb\u011Bhu t\u011Bhotenstv\u00ED pronikat placentou do krevn\u00EDho ob\u011Bhu plodu a nav\u00E1\u017E\u00ED se na fet\u00E1ln\u00ED erytrocyty, kter\u00E9 jsou n\u00E1sledn\u011B destruov\u00E1ny v retikulo-endoteli\u00E1ln\u00EDm syst\u00E9mu plodu. Rozv\u00EDj\u00ED se hemolytick\u00E9 onemocn\u011Bn\u00ED plodu a novorozence (HDFN - Haemolytic Disease of the Fetus and Newborn). Nen\u00ED-li aloimunizace matky diagnostikov\u00E1na a hemolytick\u00E9 onemocn\u011Bn\u00ED plodu nebo novorozence l\u00E9\u010Deno, m\u016F\u017Ee v\u00E9st k z\u00E1va\u017En\u00E9 perinat\u00E1ln\u00ED morbidit\u011B i mortalit\u011B. Dojde-li v pr\u016Fb\u011Bhu t\u011Bhotenstv\u00ED k prvn\u00EDmu kontaktu imunitn\u00EDho syst\u00E9mu matky s inkompatibiln\u00EDm erytrocyt\u00E1rn\u00EDm antigenem plodu, vznik\u00E1 z\u00E1va\u017En\u00E1 forma hemolytick\u00E9ho onemocn\u011Bn\u00ED ve st\u00E1vaj\u00EDc\u00EDm t\u011Bhotenstv\u00ED jen vz\u00E1cn\u011B. Z\u00E1va\u017Enou formou hemolytick\u00E9 nemoci jsou v\u011Bt\u0161inou ohro\u017Eeny antigenn\u011B inkompatibiln\u00ED plody a\u017E v n\u00E1sleduj\u00EDc\u00EDch t\u011Bhotenstv\u00EDch." .